Inflectra (Infliximab)

Prescription medicineOnly Available By Prescription

What if I find a lower price with another pharmacy?

We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!

Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.

To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.

Terms & Conditions of Program

  • Guaranteed lowest price is only valid at the time of sale.
  • We will only match the current advertised price.
  • Products must be identical and in stock at the time of placing an order with a licensed mail order pharmacy. They must be an online Canadian pharmacy with an address in Canada.
  • Products must be authentic in brand and size (same manufacturer, same country of manufacture, same pack size, same strength and same quantity).
  • Products must be new. We cannot match the price of any used, short expiry or expired product.
  • Price match can only be issued over the phone with our customer service team. Please note at this time we cannot offer price matching for the products Ozempic or Saxenda.
What is a Generic Drug?

A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.

The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.

Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.

Description

Inflectra (infliximab-dyyb) is administered via an intravenous (IV) infusion for the treatment of:

  • Crohn’s disease
  • Pediatric Crohn’s disease
  • Ulcerative colitis
  • Pediatric ulcerative colitis
  • Rheumatoid arthritis
  • Ankylosing spondylitis
  • Psoriatic arthritis
  • Plaque psoriasis
Fact Table
Formula C6428H9912N1694O1987S46
License FDA approved
Bioavailability Not applicable (intravenous administration)
Legal status Prescription only
Chemical Name Infliximab
Elimination half-life Approximately 9.5 days
Dosage (Strength) 100 mg/vial
Pregnancy Consult a healthcare provider
Brands Inflectra, Remicade, Remsima
Protein binding Not extensively bound to plasma proteins
PubChem CID 16129606
MedlinePlus a604000
ChEBI 606143
ATC code L04AB02
DrugBank DB00065
KEGG D02597
Routes of administration Intravenous

Directions

A treatment plan for you, including Inflectra dosing, will be decided by your healthcare provider. A healthcare professional will administer Inflectra IV infusion. Any questions or concerns may be referred to your healthcare provider.

Ingredients

Infliximab-dyyb is the active ingredient in Inflectra.

Dibasic sodium phosphate dihydrate, monobasic sodium phosphate monohydrate, polysorbate 80, and sucrose are the inactive ingredients.

Contraindications

Inflectra doses that are more than 5 mg per kg should not be administered to patients with moderate or severe heart failure.

Additionally, Inflectra should not be administered to patients with an allergy to any of its ingredients.

Cautions

  • Inflectra is associated with the following FDA Boxed Warning:
    • The risk for serious infections that necessitate hospitalization or may cause death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis) and infections due to other opportunistic pathogens, is increased.
    • If a patient develops a serious infection, Inflectra should be discontinued.
    • Latent TB testing should be performed. TB treatment should be started prior to initiating Inflectra if the test is positive. Active TB should be monitored in all patients during treatment, even if their first latent TB test is negative.
    • Lymphoma and other malignancies that can be fatal have occurred in children and adolescent patients treated with tumor necrosis factor (TNF) blockers such as infliximab.
    • Fatal hepatosplenic T-cell lymphoma (HSTCL) has occurred in some patients treated with TNF blockers such as infliximab. Nearly all had received azathioprine or 6-mercaptopurine with a TNF blocker at or before diagnosis. Most of the patients had Crohn’s disease or ulcerative colitis; the majority of these were adolescent or young adult males.
  • Before you start receiving Inflectra, discuss the following with your healthcare provider:
    • All the prescription and nonprescription medications you take, including vitamins, herbals, and supplements
    • Your allergies
    • Your current health problems
    • Your past medical history
    • If you are pregnant or breastfeeding
  • The following may occur during Inflectra use:
    • Invasive fungal infections or other serious infections
    • Cancers
    • Hepatitis B virus reactivation
    • Liver issues
    • Heart failure
    • Abnormal blood cell counts
    • Anaphylaxis, serum sickness-like reactions, or other hypersensitivity reactions
    • Heart attacks, arrhythmias, or other cardiovascular and cerebrovascular reactions
    • Demyelinating disease
    • Lupus-like syndrome
  • Patients on Inflectra should not receive live vaccinations.

Side Effects

Inflectra side effects include but are not limited to infections, infusion-related reactions, headache, and abdominal pain are common Inflectra side effects. Tell your healthcare provider right away if you experience worrisome or persistent side effects.

Talk to your healthcare provider about Inflectra.

Reference

Inflectra. New York, NY: Pfizer Labs; 2023.




IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.

product reviews icon Product Reviews